Novel aspects of factor XIII deficiency

L. Muszbek, Z. Bagoly, Andrea Cairo, Flora Peyvandi

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Purpose of Review: Here we review recent developments concerning the diagnosis, classification and treatment of factor XIII (FXIII) deficiency and new findings related to the pathogenesis of the disease. Recent Findings: Most recently, the International Society on Thrombosis and Haemostasis, Scientific and Standardization Committee published a guideline for the diagnosis and classification of FXIII deficiencies. Since 2009, three novel mutations causing severe bleeding diathesis were discovered in the FXIII-A gene and one in the FXIII-B gene. A newly described FXIII-A deficiency was of the extremely rare qualitative type II deficiency. The first well established founder effect was reported for a causative FXIII-A mutation. More than a quarter of all FXIII-A deficiencies are due to autoantibody, among them the first case of deficiency caused by anti-FXIII-B autoantibody was reported in the last 2 years. The safety and effectiveness of plasma FXIII concentrate for prophylaxis and treatment is now well established. The new recombinant FXIII product is currently in phase III clinical trial and the preliminary data are promising. Summary: FXIII deficiency is considered the most underdiagnosed bleeding diathesis. The recommended algorithm for its diagnosis and classification could improve the diagnostic efficiency. The preferred choice for substitution therapy is FXIII concentrate (plasma-derived or, in the future, recombinant).

Original languageEnglish
Pages (from-to)366-372
Number of pages7
JournalCurrent Opinion in Hematology
Volume18
Issue number5
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Factor XIII Deficiency
Factor XIII
Disease Susceptibility
Autoantibodies
Hemorrhage
Founder Effect
Phase III Clinical Trials
Mutation
Hemostasis
Genes
Thrombosis
Guidelines
Safety

Keywords

  • autoantibody
  • bleeding diathesis
  • factor XIII
  • factor XIII deficiency
  • replacement therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Novel aspects of factor XIII deficiency. / Muszbek, L.; Bagoly, Z.; Cairo, Andrea; Peyvandi, Flora.

In: Current Opinion in Hematology, Vol. 18, No. 5, 09.2011, p. 366-372.

Research output: Contribution to journalArticle

Muszbek, L. ; Bagoly, Z. ; Cairo, Andrea ; Peyvandi, Flora. / Novel aspects of factor XIII deficiency. In: Current Opinion in Hematology. 2011 ; Vol. 18, No. 5. pp. 366-372.
@article{43858e3c51eb4104ad890af60d877470,
title = "Novel aspects of factor XIII deficiency",
abstract = "Purpose of Review: Here we review recent developments concerning the diagnosis, classification and treatment of factor XIII (FXIII) deficiency and new findings related to the pathogenesis of the disease. Recent Findings: Most recently, the International Society on Thrombosis and Haemostasis, Scientific and Standardization Committee published a guideline for the diagnosis and classification of FXIII deficiencies. Since 2009, three novel mutations causing severe bleeding diathesis were discovered in the FXIII-A gene and one in the FXIII-B gene. A newly described FXIII-A deficiency was of the extremely rare qualitative type II deficiency. The first well established founder effect was reported for a causative FXIII-A mutation. More than a quarter of all FXIII-A deficiencies are due to autoantibody, among them the first case of deficiency caused by anti-FXIII-B autoantibody was reported in the last 2 years. The safety and effectiveness of plasma FXIII concentrate for prophylaxis and treatment is now well established. The new recombinant FXIII product is currently in phase III clinical trial and the preliminary data are promising. Summary: FXIII deficiency is considered the most underdiagnosed bleeding diathesis. The recommended algorithm for its diagnosis and classification could improve the diagnostic efficiency. The preferred choice for substitution therapy is FXIII concentrate (plasma-derived or, in the future, recombinant).",
keywords = "autoantibody, bleeding diathesis, factor XIII, factor XIII deficiency, replacement therapy",
author = "L. Muszbek and Z. Bagoly and Andrea Cairo and Flora Peyvandi",
year = "2011",
month = "9",
doi = "10.1097/MOH.0b013e3283497e3e",
language = "English",
volume = "18",
pages = "366--372",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Novel aspects of factor XIII deficiency

AU - Muszbek, L.

AU - Bagoly, Z.

AU - Cairo, Andrea

AU - Peyvandi, Flora

PY - 2011/9

Y1 - 2011/9

N2 - Purpose of Review: Here we review recent developments concerning the diagnosis, classification and treatment of factor XIII (FXIII) deficiency and new findings related to the pathogenesis of the disease. Recent Findings: Most recently, the International Society on Thrombosis and Haemostasis, Scientific and Standardization Committee published a guideline for the diagnosis and classification of FXIII deficiencies. Since 2009, three novel mutations causing severe bleeding diathesis were discovered in the FXIII-A gene and one in the FXIII-B gene. A newly described FXIII-A deficiency was of the extremely rare qualitative type II deficiency. The first well established founder effect was reported for a causative FXIII-A mutation. More than a quarter of all FXIII-A deficiencies are due to autoantibody, among them the first case of deficiency caused by anti-FXIII-B autoantibody was reported in the last 2 years. The safety and effectiveness of plasma FXIII concentrate for prophylaxis and treatment is now well established. The new recombinant FXIII product is currently in phase III clinical trial and the preliminary data are promising. Summary: FXIII deficiency is considered the most underdiagnosed bleeding diathesis. The recommended algorithm for its diagnosis and classification could improve the diagnostic efficiency. The preferred choice for substitution therapy is FXIII concentrate (plasma-derived or, in the future, recombinant).

AB - Purpose of Review: Here we review recent developments concerning the diagnosis, classification and treatment of factor XIII (FXIII) deficiency and new findings related to the pathogenesis of the disease. Recent Findings: Most recently, the International Society on Thrombosis and Haemostasis, Scientific and Standardization Committee published a guideline for the diagnosis and classification of FXIII deficiencies. Since 2009, three novel mutations causing severe bleeding diathesis were discovered in the FXIII-A gene and one in the FXIII-B gene. A newly described FXIII-A deficiency was of the extremely rare qualitative type II deficiency. The first well established founder effect was reported for a causative FXIII-A mutation. More than a quarter of all FXIII-A deficiencies are due to autoantibody, among them the first case of deficiency caused by anti-FXIII-B autoantibody was reported in the last 2 years. The safety and effectiveness of plasma FXIII concentrate for prophylaxis and treatment is now well established. The new recombinant FXIII product is currently in phase III clinical trial and the preliminary data are promising. Summary: FXIII deficiency is considered the most underdiagnosed bleeding diathesis. The recommended algorithm for its diagnosis and classification could improve the diagnostic efficiency. The preferred choice for substitution therapy is FXIII concentrate (plasma-derived or, in the future, recombinant).

KW - autoantibody

KW - bleeding diathesis

KW - factor XIII

KW - factor XIII deficiency

KW - replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=80051781189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051781189&partnerID=8YFLogxK

U2 - 10.1097/MOH.0b013e3283497e3e

DO - 10.1097/MOH.0b013e3283497e3e

M3 - Article

VL - 18

SP - 366

EP - 372

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 5

ER -